Establishing an institutional model for the administration of tositumomab and iodine I 131 tositumomab

Hohenstein, Maribeth; Augustine, Samuel C.; Rutar, Frank J.; Vose, Julie M.

doi:10.1053/sonc.2003.23801

Cited by 6 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Details of the Bexxar regimen are illustrated in Figure 4 [50]. Oral iodine supplements to block I-131 uptake by the thyroid gland are administered beginning 1 day before administering the dosimetric infusion and continuing for 2 weeks after the therapeutic dose.…”

Section: Patient-specific Dosingmentioning

confidence: 99%

“…This approach was pio- 167 Bexxar for NHL Office/approved facility Outpatient neered by investigators at the University of Nebraska Medical Center (UNMC) (Omaha, NE) and the Hoag Cancer Center (Newport Beach, CA) [50,51]. The UNMC treatment team is composed of hematology/oncology and nuclear medicine personnel who ensure the safe delivery of Bexxar and are responsible for providing clear and comprehensive patient education to maintain the safety of caregivers and family members when the patient is released.…”

Section: Administration In An Outpatient Oncology Clinicmentioning

confidence: 99%

“…The UNMC treatment team is composed of hematology/oncology and nuclear medicine personnel who ensure the safe delivery of Bexxar and are responsible for providing clear and comprehensive patient education to maintain the safety of caregivers and family members when the patient is released. Members of the UNMC treatment team have various responsibilities [50]:…”

Section: Administration In An Outpatient Oncology Clinicmentioning

confidence: 99%

See 2 more Smart Citations

Bexxar®: Novel Radioimmunotherapy for the Treatment of Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma

Vose

2004

The Oncologist

Self Cite

View full text Add to dashboard Cite

Purpose. Immunotherapy using monoclonal antibodies to specifically target B cells has provided new hope to many patients with indolent lymphomas, particularly those with chemotherapy-refractory disease. Lymphomas are extremely sensitive to radiation, and significant progress has been made over the last decade in the development of radioimmunotherapy with anti-CD20 antibodies.Materials and Methods. Herein we review clinical experience with tositumomab and iodine I 131 tositumomab (Bexxar ® ; Corixa Corporation; South San Francisco, CA; and GlaxoSmithKline; Philadelphia, PA) in patients with non-Hodgkin's lymphoma.Results. Therapy with Bexxar has demonstrated high response rates and long durations of response compared with unconjugated anti-CD20 antibodies in patients with relapsed low-grade and transformed low-grade non-Hodgkin's lymphomas. Iodine-131 (I-131) has a long history of clinical experience, an excellent safety record, and favorable nuclear and pharmacologic properties. Importantly, the gamma emissions of iodine-131 facilitate accurate dosimetry to calculate the appropriate patient-specific therapeutic activity to deliver a predetermined total-body dose of radiation, thereby minimizing hematologic toxicity. In clinical trials of Bexxar, objective response rates ranged from 54%-71% in heavily pretreated patients. In the pivotal trial, the number of patients with a longer duration of response after treatment with Bexxar was significantly greater than the number of patients with a longer duration of response after their last qualifying chemotherapy regimen. In 76 newly diagnosed patients, the objective response rate was 97%, and 63% of patients achieved complete responses.Conclusion. These data suggest that Bexxar will become an important new option in the treatment of indolent lymphoma. The Oncologist 2004;9:160-172 The Oncologist 2004;9:160-172 www.TheOncologist.comCorrespondence: Julie M. Vose, M.D., Department of Internal Medicine, University of Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, Nebraska, 68198-7680, USA. Telephone: 402-559-3848; Fax: 402-559-6520; e-mail: jmvose@unmc.edu Received February 21, 2003; accepted for publication February 11, 2004. ©AlphaMed Press 1083-7159/2004 The Oncologist ® Lymphoma LEARNING OBJECTIVESAfter completing this course, the reader will be able to:1. Describe advances in clinical radioimmunotherapy. Discuss ongoing translational research in radioimmunotherapy.3. Identify future directions for radioimmunotherapy in cancer medicine.Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com CME CME This material is protected by U.S.

show abstract

Section: Patient-specific Dosingmentioning

confidence: 99%

Section: Administration In An Outpatient Oncology Clinicmentioning

confidence: 99%

Section: Administration In An Outpatient Oncology Clinicmentioning

confidence: 99%

See 1 more Smart Citation